The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Gut microbiome in HCC – Mechanisms, diagnosis and therapy
Abstract
The microbiome exerts essential functions in health and disease, modulating key processes in metabolism, inflammation and immunity. Recent evidence has revealed a key role of the microbiome in carcinogenesis as well as anti-cancer immune responses in mouse models and patients. Herein, we will review functions of the gut microbiome in hepatocellular carcinoma (HCC), the third leading cause of worldwide cancer mortality. The majority of HCC develops in patients with chronic liver disease, caused by viral hepatitis, non-alcoholic fatty liver disease (NAFLD) and alcohol-related fatty liver disease. In this review, we will discuss mechanisms by which the gut-liver axis promotes the development of HCC in mouse models and patients, including dysbiosis, the leaky gut and bacterial metabolites, with a particular focus on NAFLD as the fastest growing cause of HCC development. Moreover, we will review recent progress in harnessing the gut microbiome as a potential diagnostic tool and novel therapeutic target in patients with HCC, in particular in the setting of immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease
Wang, Z., Klipfell, E., Bennett, B. J., Koeth, R., Levison, B. S., DuGar, B., Feldstein, A. E., Britt, E. B., Fu, X., Chung, Y.-M., et al. (2011) · Nature · doi:10.1038/nature09922 · Cited by 5,597
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy
Sivan, A., Corrales, L., Hubert, N., Williams, J. B., Aquino-Michaels, K., Earley, Z. M., Benyamin, F. W., Man Lei, Y., Jabri, B., Alegre, M.-L., et al. (2015) · Science · doi:10.1126/science.aac4255 · Cited by 3,888
El-Serag, H. B. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1001683 · Cited by 3,529
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
Vétizou, M., Pitt, J. M., Daillère, R., Lepage, P., Waldschmitt, N., Flament, C., Rusakiewicz, S., Routy, B., Roberti, M. P., Duong, C. P. M., et al. (2015) · Science · doi:10.1126/science.aad1329 · Cited by 3,488
The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients
Matson, V., Fessler, J., Bao, R., Chongsuwat, T., Zha, Y., Alegre, M.-L., Luke, J. J., & Gajewski, T. F. (2018) · Science · doi:10.1126/science.aao3290 · Cited by 3,107
Depommier, C., Everard, A., Druart, C., Plovier, H., Van Hul, M., Vieira-Silva, S., Falony, G., Raes, J., Maiter, D., Delzenne, N. M., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0495-2 · Cited by 2,357
Commensal Bacteria Control Cancer Response to Therapy by Modulating the Tumor Microenvironment
Iida, N., Dzutsev, A., Stewart, C. A., Smith, L., Bouladoux, N., Weingarten, R. A., Molina, D. A., Salcedo, R., Back, T., Cramer, S., et al. (2013) · Science · doi:10.1126/science.1240527 · Cited by 2,251
Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome
Yoshimoto, S., Loo, T. M., Atarashi, K., Kanda, H., Sato, S., Oyadomari, S., Iwakura, Y., Oshima, K., Morita, H., Hattori, M., et al. (2013) · Nature · doi:10.1038/nature12347 · Cited by 2,219
Alterations of the human gut microbiome in liver cirrhosis
Qin, N., Yang, F., Li, A., Prifti, E., Chen, Y., Shao, L., Guo, J., Le Chatelier, E., Yao, J., Wu, L., et al. (2014) · Nature · doi:10.1038/nature13568 · Cited by 2,177
The Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide
Viaud, S., Saccheri, F., Mignot, G., Yamazaki, T., Daillère, R., Hannani, D., Enot, D. P., Pfirschke, C., Engblom, C., Pittet, M. J., et al. (2013) · Science · doi:10.1126/science.1240537 · Cited by 2,050
Zhu, L., Baker, S. S., Gill, C., Liu, W., Alkhouri, R., Baker, R. D., & Gill, S. R. (2013) · Hepatology · doi:10.1002/hep.26093 · Cited by 1,708
Schwabe, R. F., & Jobin, C. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3610 · Cited by 1,689
Self-citationGut microbiome–mediated bile acid metabolism regulates liver cancer via NKT cells
Ma, C., Han, M., Heinrich, B., Fu, Q., Zhang, Q., Sandhu, M., Agdashian, D., Terabe, M., Berzofsky, J. A., Fako, V., et al. (2018) · Science · doi:10.1126/science.aan5931 · Cited by 1,508
Self-citationThe gut-liver axis and the intersection with the microbiome
Tripathi, A., Debelius, J., Brenner, D. A., Karin, M., Loomba, R., Schnabl, B., & Knight, R. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0011-z · Cited by 1,480
The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy
Gopalakrishnan, V., Helmink, B. A., Spencer, C. N., Reuben, A., & Wargo, J. A. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.015 · Cited by 1,392
Promotion of Hepatocellular Carcinoma by the Intestinal Microbiota and TLR4
Dapito, D. H., Mencin, A., Gwak, G.-Y., Pradere, J.-P., Jang, M.-K., Mederacke, I., Caviglia, J. M., Khiabanian, H., Adeyemi, A., Bataller, R., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.007 · Cited by 1,346
Self-citationThe microbiome, cancer, and cancer therapy
Helmink, B. A., Khan, M. A. W., Hermann, A., Gopalakrishnan, V., & Wargo, J. A. (2019) · Nature Medicine · doi:10.1038/s41591-019-0377-7 · Cited by 1,200
Molecular mechanisms of alcohol-mediated carcinogenesis
Seitz, H. K., & Stickel, F. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2191 · Cited by 1,138
Loomba, R., Seguritan, V., Li, W., Long, T., Klitgord, N., Bhatt, A., Dulai, P. S., Caussy, C., Bettencourt, R., Highlander, S. K., et al. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.04.001 · Cited by 1,123
Gao, Q., Qiu, S.-J., Fan, J., Zhou, J., Wang, X.-Y., Xiao, Y.-S., Xu, Y., Li, Y.-W., & Tang, Z.-Y. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.4565 · Cited by 1,110
The immunology of hepatocellular carcinoma
Ringelhan, M., Pfister, D., O’Connor, T., Pikarsky, E., & Heikenwalder, M. (2018) · Nature Immunology · doi:10.1038/s41590-018-0044-z · Cited by 1,076
Dumas, M.-E., Barton, R. H., Toye, A., Cloarec, O., Blancher, C., Rothwell, A., Fearnside, J., Tatoud, R., Blanc, V., Lindon, J. C., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601056103 · Cited by 1,042
Fu, J., Xu, D., Liu, Z., Shi, M., Zhao, P., Fu, B., Zhang, Z., Yang, H., Zhang, H., Zhou, C., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.102 · Cited by 897
Wild Mouse Gut Microbiota Promotes Host Fitness and Improves Disease Resistance
Rosshart, S. P., Vassallo, B. G., Angeletti, D., Hutchinson, D. S., Morgan, A. P., Takeda, K., Hickman, H. D., McCulloch, J. A., Badger, J. H., Ajami, N. J., et al. (2017) · Cell · doi:10.1016/j.cell.2017.09.016 · Cited by 862
Enteric dysbiosis associated with a mouse model of alcoholic liver disease
Yan, A. W., Fouts, D. E., Brandl, J., Stärkel, P., Torralba, M., Schott, E., Tsukamoto, H., Nelson, K. E., Brenner, D. A., & Schnabl, B. (2011) · Hepatology · doi:10.1002/hep.24018 · Cited by 791
Ren, Z., Li, A., Jiang, J., Zhou, L., Yu, Z., Lu, H., Xie, H., Chen, X., Shao, L., Zhang, R., et al. (2019) · Gut · doi:10.1136/gutjnl-2017-315084 · Cited by 764
Wolf, M. J., Adili, A., Piotrowitz, K., Abdullah, Z., Boege, Y., Stemmer, K., Ringelhan, M., Simonavicius, N., Egger, M., Wohlleber, D., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.09.003 · Cited by 678
Machine Learning Meta-analysis of Large Metagenomic Datasets: Tools and Biological Insights
Pasolli, E., Truong, D. T., Malik, F., Waldron, L., & Segata, N. (2016) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1004977 · Cited by 659
Ponziani, F. R., Bhoori, S., Castelli, C., Putignani, L., Rivoltini, L., Del Chierico, F., Sanguinetti, M., Morelli, D., Paroni Sterbini, F., Petito, V., et al. (2019) · Hepatology · doi:10.1002/hep.30036 · Cited by 654
Parlesak, A., Schäfer, C., Schütz, T., Bode, J. C., & Bode, C. (2000) · Journal of Hepatology · doi:10.1016/s0168-8278(00)80242-1 · Cited by 647
The gut microbiome and liver cancer: mechanisms and clinical translation
Yu, L.-X., & Schwabe, R. F. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.72 · Cited by 634
Self-citationInflammation-induced IgA+ cells dismantle anti-liver cancer immunity
Shalapour, S., Lin, X.-J., Bastian, I. N., Brain, J., Burt, A. D., Aksenov, A. A., Vrbanac, A. F., Li, W., Perkins, A., Matsutani, T., et al. (2017) · Nature · doi:10.1038/nature24302 · Cited by 589
Dysregulated Microbial Fermentation of Soluble Fiber Induces Cholestatic Liver Cancer
Singh, V., Yeoh, B. S., Chassaing, B., Xiao, X., Saha, P., Aguilera Olvera, R., Lapek, J. D., Zhang, L., Wang, W.-B., Hao, S., et al. (2018) · Cell · doi:10.1016/j.cell.2018.09.004 · Cited by 532
Loo, T. M., Kamachi, F., Watanabe, Y., Yoshimoto, S., Kanda, H., Arai, Y., Nakajima-Takagi, Y., Iwama, A., Koga, T., Sugimoto, Y., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0932 · Cited by 478
Balmer, M. L., Slack, E., de Gottardi, A., Lawson, M. A. E., Hapfelmeier, S., Miele, L., Grieco, A., Van Vlierberghe, H., Fahrner, R., Patuto, N., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008618 · Cited by 470
Garnelo, M., Tan, A., Her, Z., Yeong, J., Lim, C. J., Chen, J., Lim, K. H., Weber, A., Chow, P., Chung, A., et al. (2017) · Gut · doi:10.1136/gutjnl-2015-310814 · Cited by 461
Gut microbiota promotes tumor growth in mice by modulating immune response
Sethi, V., Kurtom, S., Tarique, M., Lavania, S., Malchiodi, Z., Hellmund, L., Zhang, L., Sharma, U., Giri, B., Garg, B., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.04.001 · Cited by 403
Toll-Like Receptor Signaling in the Liver
Schwabe, R. F., Seki, E., & Brenner, D. A. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.01.038 · Cited by 401
Self-citationImmune regulation by microbiome metabolites
Kim, C. H. (2018) · Immunology · doi:10.1111/imm.12930 · Cited by 375
Lin, R.-S., Lee, F.-Y., Lee, S.-D., Tsai, Y.-T., Lin, H. C., Rei-Hwa, L., Wan-Ching, H., Cheng-Chun, H., Sun-Sang, W., & Kwang-Juei, L. (1995) · Journal of Hepatology · doi:10.1016/0168-8278(95)80424-2 · Cited by 355
Yu, L.-X., Yan, H.-X., Liu, Q., Yang, W., Wu, H.-P., Dong, W., Tang, L., Lin, Y., He, Y.-Q., Zou, S.-S., et al. (2010) · Hepatology · doi:10.1002/hep.23845 · Cited by 349
A Gut Microbiome Signature for Cirrhosis Due to Nonalcoholic Fatty Liver Disease
Caussy, C., Tripathi, A., Humphrey, G., Bassirian, S., Singh, S., Faulkner, C., Bettencourt, R., Rizo, E., Richards, L., Xu, Z. Z., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09455-9 · Cited by 338
Gäbele, E., Dostert, K., Hofmann, C., Wiest, R., Schölmerich, J., Hellerbrand, C., & Obermeier, F. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.02.035 · Cited by 324
TMAO: A small molecule of great expectations
Ufnal, M., Zadlo, A., & Ostaszewski, R. (2015) · Nutrition · doi:10.1016/j.nut.2015.05.006 · Cited by 319
Exploring the emerging role of the microbiome in cancer immunotherapy
Fessler, J., Matson, V., & Gajewski, T. F. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0574-4 · Cited by 319
Bacterial translocation and changes in the intestinal microbiome in mouse models of liver disease
Fouts, D. E., Torralba, M., Nelson, K. E., Brenner, D. A., & Schnabl, B. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.01.019 · Cited by 311
Targeted and Immune-Based Therapies for Hepatocellular Carcinoma
Greten, T. F., Lai, C. W., Li, G., & Staveley-O’Carroll, K. F. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.09.051 · Cited by 294
Self-citationAltekruse, S. F., McGlynn, K. A., Dickie, L. A., & Kleiner, D. E. (2012) · Hepatology · doi:10.1002/hep.24710 · Cited by 262
Arihara, F., Mizukoshi, E., Kitahara, M., Takata, Y., Arai, K., Yamashita, T., Nakamoto, Y., & Kaneko, S. (2013) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-013-1447-1 · Cited by 252
Mouse models of hepatocellular carcinoma: an overview and highlights for immunotherapy research
Brown, Z. J., Heinrich, B., & Greten, T. F. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0033-6 · Cited by 245
Self-citationBellot, P., Garc´ıa-Paga´n, J. C., France´s, R., Abraldes, J. G., Navasa, M., Pe´rez-Mateo, M., Such, J., & Bosch, J. (2010) · Hepatology · doi:10.1002/hep.23918 · Cited by 219
Elinav, E., Garrett, W. S., Trinchieri, G., & Wargo, J. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0155-3 · Cited by 215
Chou, H.-H., Chien, W.-H., Wu, L.-L., Cheng, C.-H., Chung, C.-H., Horng, J.-H., Ni, Y.-H., Tseng, H.-T., Wu, D., Lu, X., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1424775112 · Cited by 211
Liu, Q., Li, F., Zhuang, Y., Xu, J., Wang, J., Mao, X., Zhang, Y., & Liu, X. (2019) · Gut Pathogens · doi:10.1186/s13099-018-0281-6 · Cited by 208
Grąt, M., Wronka, K. M., Krasnodębski, M., Masior, Ł., Lewandowski, Z., Kosińska, I., Grąt, K., Stypułkowski, J., Rejowski, S., Wasilewicz, M., et al. (2016) · Transplantation Proceedings · doi:10.1016/j.transproceed.2016.01.077 · Cited by 206
Adaptive immunity suppresses formation and progression of diethylnitrosamine-induced liver cancer
Schneider, C., Teufel, A., Yevsa, T., Staib, F., Hohmeyer, A., Walenda, G., Zimmermann, H. W., Vucur, M., Huss, S., Gassler, N., et al. (2012) · Gut · doi:10.1136/gutjnl-2011-301116 · Cited by 182
Targets for immunotherapy of liver cancer
Greten, T. F., & Sangro, B. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.09.007 · Cited by 168
Self-citationToll-like Receptor 4 and Hepatic Fibrogenesis
Pradere, J.-P., Troeger, J., Dapito, D., Mencin, A., & Schwabe, R. (2010) · Seminars in Liver Disease · doi:10.1055/s-0030-1255353 · Cited by 158
Self-citationEngstler, A. J., Aumiller, T., Degen, C., Dürr, M., Weiss, E., Maier, I. B., Schattenberg, J. M., Jin, C. J., Sellmann, C., & Bergheim, I. (2015) · Gut · doi:10.1136/gutjnl-2014-308379 · Cited by 140
Oellgaard, J., Winther, S. A., Hansen, T. S., Rossing, P. R., & von Scholten, B. J. (2017) · Current Pharmaceutical Design · doi:10.2174/1381612823666170622095324 · Cited by 138
Yamada, S., Takashina, Y., 渡辺, 光., Nagamine, R., Saito, Y., Kamada, N., & Saito, H. (2018) · Oncotarget · doi:10.18632/oncotarget.24066 · Cited by 132
Chng, K. R., Chan, S. H., Ng, A. H. Q., Li, C., Jusakul, A., Bertrand, D., Wilm, A., Choo, S. P., Tan, D. M. Y., Lim, K. H., et al. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.04.034 · Cited by 129
Microbiota—myeloid cell crosstalk beyond the gut
Gorjifard, S., & Goldszmid, R. S. (2016) · Journal of Leukocyte Biology · doi:10.1189/jlb.3ri0516-222r · Cited by 104
Dual Role of the Adaptive Immune System in Liver Injury and Hepatocellular Carcinoma Development
Endig, J., Buitrago‐Molina, L. E., Marhenke, S., Reisinger, F., Saborowski, A. L., Schuett, J., Limbourg, F. P., Koenecke, C., Schreder, A., Michael, A., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.06.009 · Cited by 84
Observations on the formation of ethanol in the intestinal tract in man
Blomstrand, R. (1971) · Life Sciences · doi:10.1016/0024-3205(71)90194-9 · Cited by 58
Achiwa, K., Ishigami, M., Ishizu, Y., Kuzuya, T., Honda, T., Hayashi, K., Hirooka, Y., Katano, Y., & Goto, H. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.12.012 · Cited by 54
Correlation, consequence, and functionality in microbiome‐immune interplay
Pabst, O. (2017) · Immunological Reviews · doi:10.1111/imr.12584 · Cited by 17
Cited by
Immunotherapies for hepatocellular carcinoma
Llovet, J. M., Castet, F., Heikenwalder, M., Maini, M. K., Mazzaferro, V., Pinato, D. J., Pikarsky, E., Zhu, A. X., & Finn, R. S. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00573-2 · Cited by 1,843
The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma
Donne, R., & Lujambio, A. (2023) · Hepatology · doi:10.1002/hep.32740 · Cited by 631
Global Epidemiology and Genetics of Hepatocellular Carcinoma
Toh, M. R., Wong, E. Y. T., Wong, S. H., Ng, A. W. T., Loo, L.-H., Chow, P. K.-H., & Ngeow, J. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.01.033 · Cited by 583
Global epidemiology of alcohol-associated cirrhosis and HCC: trends, projections and risk factors
Huang, D. Q., Mathurin, P., Cortez-Pinto, H., & Loomba, R. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00688-6 · Cited by 553
Gut microbiome, liver immunology, and liver diseases
Wang, R., Tang, R., Li, B., Ma, X., Schnabl, B., & Tilg, H. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-00592-6 · Cited by 466
Metadata
- Authors
- Schwabe, R. F., & Greten, T. F.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2020-02
- Volume
- 72
- Issue
- 2
- Pages
- 230-238
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W2999153903
- Cited by
- 363
- References
- 69
- FWCI
- 13.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.